Genomic screening for blood cancer offers Australians with aggressive cancers access to personalised treatments and clinical trials.
Discover how next-gen sequencing is revolutionising blood cancer treatment in Australia, improving AML diagnosis and saving lives.
A blood cancer drug 30 years in the making has been approved for use in Australia, giving hope to Australians with myelofibrosis, a rare form of blood cancer.
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary new type of treatment that ‘trains’ a patient’s own immune cells to seek out and kill cancer.
In the ever-evolving landscape of blood cancer research, the quest to combat blood cancer continues to push boundaries. The New Directions in Leukaemia Research (NDLR) event in Adelaide last month brought together leading minds in the field to discuss breakthroughs, challenges, and the future of leukaemia treatment. From cutting-edge advancements in therapies to the promise of personalised medicine, the conference, sponsored by the Leukaemia Foundation, shed light on the latest discoveries and strategies shaping the fight against leukaemia.
Access to clinical trials of novel treatments, including immune checkpoint inhibitors and CAR T-cell therapy, could be a game changer for these patients, according to Dr Colm Keane. He is a clinical haematologist at the Princess Alexandra Hospital in Brisbane and a brain lymphoma researcher at the University of Queensland's Frazer Institute.
Haematologist, Dr Jessica Elliott’s interest is researching T-cell mediated skin disorders, in particular, two clinically similar but biologically divergent conditions – cutaneous T-cell lymphomas (CTCL) (a subtype of skin lymphoma) and cutaneous graft-versus-host disease (GVHD).
